声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。2025年5月14日,艾伯维和ADARx Pharmaceuticals宣布了一项合作和许可选择协议,以开发涵盖神经科学、免疫学和肿瘤学等多个疾病领域的siRNA疗法。根据协议条款,ADARx 将获得3.35 亿美元的预付款,并有资格获得数十亿美元的额外...
Source Link声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。2025年5月14日,艾伯维和ADARx Pharmaceuticals宣布了一项合作和许可选择协议,以开发涵盖神经科学、免疫学和肿瘤学等多个疾病领域的siRNA疗法。根据协议条款,ADARx 将获得3.35 亿美元的预付款,并有资格获得数十亿美元的额外...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.